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Chronic gut inflammatory diseases are associated with disruption
of intestinal epithelial barriers and impaired mucosal immunity.
HIV-1 (HIV) causes depletion of mucosal CD4+ T cells early in in-
fection and disruption of gut epithelium, resulting in chronic in-
flammation and immunodeficiency. Although antiretroviral therapy
(ART) is effective in suppressing viral replication, it is incapable of
restoring the “leaky gut,” which poses an impediment for HIV cure
efforts. Strategies are needed for rapid repair of the epithelium to
protect intestinal microenvironments and immunity in inflamed gut.
Using an in vivo nonhuman primate intestinal loop model of HIV/
AIDS, we identified the pathogenic mechanism underlying sus-
tained disruption of gut epithelium and explored rapid repair of
gut epithelium at the intersection of microbial metabolism. Molecular,
immunological, and metabolomic analyses revealed marked loss
of peroxisomal proliferator-activated receptor-α (PPARα) signal-
ing, predominant impairment of mitochondrial function, and ep-
ithelial disruption both in vivo and in vitro. To elucidate pathways
regulating intestinal epithelial integrity, we introduced probiotic
Lactobacillus plantarum into Simian immunodeficiency virus (SIV)-
inflamed intestinal lumen. Rapid recovery of the epithelium oc-
curred within 5 h of L. plantarum administration, independent of
mucosal CD4+ T cell recovery, and in the absence of ART. This in-
testinal barrier repair was driven by L. plantarum-induced PPARα
activation and restoration of mitochondrial structure and fatty acid
β-oxidation. Our data highlight the critical role of PPARα at the in-
tersection between microbial metabolism and epithelial repair in
virally inflamed gut and as a potential mitochondrial target for re-
storing gut barriers in other infectious or gut inflammatory diseases.
HIV/AIDS | SIV | gut epithelium | mitochondria | PPARα
Current antiretroviral therapy (ART) has transformed HIV-1(HIV) infection into a manageable chronic disease, but not
consistently led to complete immune recovery (1). Gut-associated
lymphoid tissue is an early target of HIV for establishment of
persistent viral reservoirs and chronic inflammation. Severe loss of
mucosal CD4+ T cells and disruption of gut epithelial barriers occur
very early in HIV infection in humans and in Simian immuno-
deficiency virus (SIV)-infected nonhuman primate model of
AIDS, and precede CD4+ T cell loss in peripheral blood (2, 3).
Importantly, early onset of gut epithelial barrier disruption oc-
curs prior to severe mucosal CD4+ T cell depletion and was
attributed to mucosal IL-1β production and NF-κB activation
(4). Initiation of ART during early HIV and SIV infections lead
to recovery of mucosal CD4+ T cells and gut epithelial barriers,
while the recovery is substantially delayed or incomplete when
ART is initiated late during infection (5–8). Leaky gut epithelial
barriers and loss of Th17 CD4+ T cell responses contribute to
microbial translocation and to mucosal and systemic inflammation
(9–11). Although ART is effective in suppressing HIV pro-
duction, it does not have capacity to target the repair of dis-
rupted gut mucosal compartment. Therapeutic interventions that
also target epithelial barrier repair for HIV infection need further
investigation.
Mitochondria are the main source of energy metabolism and
serve as master regulators for the cell survival, function, me-
tabolism, and immunity (12). Mitochondrial dysfunction, man-
ifested as increased mitochondrial free-radical production and
reduced ATP production, is reported in acute and chronic gastro-
intestinal diseases with impaired epithelial barriers (13). However, a
critical gap of knowledge exists at understanding the role of mito-
chondrial metabolism and function in the gut epithelial barrier in-
tegrity in HIV and SIV infections. Mitochondrial dysfunction
exhibited by altered oxidative phosphorylation and fatty acid
oxidation was observed in CD4+ T cells from HIV+ immunologic
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nonresponders receiving long-term ART (14). ART-associated
lipodystrophy also involves mitochondrial toxicity (15, 16). HIV
antigens can induce mitochondrial damage and apoptosis in T
and neuronal cell lines in vitro (17, 18). Deciphering the role of
mitochondrial function in gut epithelial barrier integrity in vivo
can provide new therapeutic strategies for restoring mucosal
immunity.
Gut epithelial cell homeostasis is regulated by commensal
microbes, which dampen gut inflammation and enhance mucosal
immunity to pathogens (19). Dysbiosis of gut microbiota is
reported in advanced HIV and SIV infections (20–22). Potential
beneficial effects of a commercial probiotic supplementation in
HIV-infected individuals could not be distinguished from effects
of ART (23). We previously reported that introduction of Lacto-
bacillus plantarum, a commensal microbe with probiotic activ-
ity, into the small intestinal lumen during early SIV infection
rapidly restored the gut epithelial barrier integrity by dampening
NF-κB activation and inflammatory cytokine expression (4).
However, it is not known whether L. plantarum can rapidly target
the repair of gut epithelial barriers in vivo during advanced
chronic SIV infection, especially prior to mucosal CD4+ T cell
restoration. In this study, we utilized an SIV model to investigate
mechanisms of gut epithelial barrier dysfunction in chronic SIV
infection and to decipher molecular pathways that can directly
reverse epithelial damage independent of mucosal immune re-
covery following L. plantarum administration. Mitochondrial
metabolic dysfunction was prominent as evidenced by decreased
mitochondrial fatty acid β-oxidation and disrupted morphology
and correlated with increased IL-1β expression and epithelial
barrier disruption. Within 5 h of L. plantarum administration,
intestinal barrier integrity was rapidly restored by activating
peroxisome proliferator-activated receptor-α (PPARα), and en-
hancing mitochondrial morphology and function and reduced
IL-1β production. Remarkably, this repair occurred independent
of mucosal CD4+ T cell restoration and in the absence of ART.
Fenofibrate, a PPARα agonist, reversed HIV antigen-induced
alterations in mitochondrial bioenergetics and epithelial barrier
disruption in epithelial cells in vitro. In summary, we identified a
mechanism of PPARα-mediated restoration of mitochondrial
function by leveraging L. plantarum metabolism to renew the gut
epithelium and mucosal immunity and counteract HIV and SIV
pathogenic effects.
Results
Increased Mucosal IL-1β Expression Coinciding with Impaired Intestinal
Epithelial Barriers in Advanced SIV Infection despite Late Initiation of
ART. We previously reported the onset of gut epithelial barrier
impairment at 2.5 d post-SIV infection. The disruption of ZO-
1 and claudin-1 tight junctions occurred prior to the gut mucosal
CD4+ T cell loss and correlated with rapid induction of the
proinflammatory cytokine IL-1β in intestinal Paneth cells (4). We
sought to determine whether mucosal IL-1β expression persists
during chronic SIV infection and contributes to sustained epi-
thelial barrier disruption. Productive viral infection was evident by
high levels of SIV RNA (Fig. 1A) and CD4+ T cell loss in pe-
ripheral blood (Fig. 1B), as well in the gut tissue (SI Appendix, Fig.
S1). Immunohistochemical analysis showed decreased expression
of ZO-1 tight junction protein and discontinuous, stippled ap-
pearance of its distribution compared to SIV− controls (Fig. 1 C
and D), suggesting that the gut epithelial barrier disruption
persists during chronic SIV infection. Similar changes were
detected for other tight junction proteins, including e-cadherin
and occludin (SI Appendix, Fig. S2). Transcriptomic analysis
showed the decreased expression of genes regulating gut barrier
function, including adherens junctions, gap junctions, tight
junctions, and secretory and digestive enzymes. (SI Appendix,
Fig. S3). Mucosal IL-1β expression remained elevated during
chronic viral infection and was primarily localized to the base of
intestinal crypts (Fig. 1 E and F). Increased expression of the
genes downstream to IL-1β signaling was also detected in SIV
infection (Fig. 1G).
Next, we sought to examine whether initiation of ART in
chronic SIV infection and suppression of viral loads would lead
to the reduction of gut mucosal IL-1β expression and recovery of
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Fig. 1. Gut epithelial barrier disruption, mucosal CD4+ T cell depletion, and IL-1β expression persist in advanced SIV infection despite late initiation of ART.
(A) Viral loads and (B) CD4+ T cell numbers were measured in peripheral blood of SIV-infected rhesus macaques (n = 3) and those treated with ART for >10-wk
(n = 5). (C) Immunostaining showed altered distribution of tight junction protein ZO-1 (magnification: 63×) in gut epithelium during SIV infection despite
ART, as shown in D semiquantitative analysis by Imaris v8.2. (E) Production of IL-1β (magnification: 20×) from intestinal crypts was increased in SIV infection
and did not change after initiation of ART, as shown by (F) semiquantitative analysis on Imaris v8.2. (G) A heatmap dendrogram of IL-1β related genes was
analyzed from gene-expression microarray of gut tissue. N.S., not significant.
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gut epithelium. We obtained gut tissue samples from 8 SIV-
infected animals from a previous study (7). ART was initiated
at 10-wk postinfection and continued for at least 10 more weeks.
ART did not result in complete suppression of plasma viral loads
(Fig. 1A) or full CD4+ T cell recovery in both peripheral blood
and gut tissue (Fig. 1B and SI Appendix, Fig. S1). It did not cause
a significant decrease in IL-1β expression in intestinal crypts (Fig.
1 E and F). Thus, the gut mucosal recovery during late ART is
not rapid and would require extended therapeutic intervention.
Mitochondrial Impairment and Intestinal Epithelial Barrier Disruption
in SIV/HIV Infection. To identify cellular mechanisms contributing
to the sustained epithelial barrier dysfunction during chronic SIV
infection, we performed an untargeted metabolomic analysis of
gut luminal contents from SIV-infected macaques compared to
uninfected controls. Detection of metabolites in the luminal
compartment revealed new insights on host–microbe interaction,
cometabolism, and their common metabolic pathways. These
metabolites were produced by gut microbiota and the host.
Metabolomic analysis identified pathways of fatty acid metabo-
lism to be highly modulated in SIV infected gut (Fig. 2 A and B,
red arrows). An increased accumulation of short- and medium-
chain acyl-carnitines compared to free carnitines (Fig. 2C) was
observed in SIV infection despite no significant changes in the
ratio of long and very-long acylcarnitine to free carnitines (Fig.
2D). This reflected a defect in mitochondrial fatty acid β-oxidation
that is independent of carnitine palmitoyl transporters, which
shuttle only long-chain fatty acids into the mitochondria (Fig. 2E).
If these metabolites are of host origin, our data suggest that im-
paired mitochondrial fatty acid β-oxidation, which provides sig-
nificant ATP to gut tissue, may contribute to gut epithelial barrier
disruption. As the reducing equivalents from carbohydrates and
fatty acids are harnessed by FADH2 and NADH for mitochondrial
oxidation at the level of the electron transport chain, the enrich-
ment in tryptophan (Trp) metabolism may suggest an increase in
downstream NAD+ metabolism (Fig. 2B). This was supported by
higher and lower concentrations of Trp-derived quinolate and
nicotinate ribonucleoside, respectively, as a potential mechanism
to increase NAD levels via de novo synthesis (SI Appendix, Fig.
S4A). A reduction in metabolites involved in phospholipid compo-
sition was observed in SIV infection, whereas higher trimethylamine
N-oxide levels indicate altered cholesterol metabolism with an
increased deposition of cholesterol within the gut wall (SI Ap-
pendix, Fig. S4B). Changes in these processes (i.e., ATP-derived
mitochondrial fatty acid oxidation, NAD+ metabolism, and
phospholipid contents) may contribute to the decrease in the
epithelial barrier integrity. Levels of acylcarnitine metabolites
were negatively correlated with tight junction protein ZO-1 ex-
pression, highlighting the link between mitochondrial fatty acid
β-oxidation and gut permeability in chronic SIV infection in vivo.
No significant correlations were found with pyrimidine metabo-
lism (SI Appendix, Fig. S5). Transcriptomic analysis revealed re-
duced mucosal gene expression of proteins associated with fatty
acid metabolism in SIV-infected animals compared to uninfected
controls, further validating impairment of mitochondrial fatty acid
β-oxidation in the gut during SIV infection (Fig. 2F).
The impairment of mitochondrial fatty acid β-oxidation in SIV
infection seem to also involve stages of transporting, tagging, and
catabolizing fatty acids. Our findings in chronic SIV infection
were also found to occur in HIV infection. We analyzed the
gene-expression data from our previous study of gut biopsies from
therapy-naive patients during primary HIV infection (2). Tran-
scriptomic analyses revealed that the expression of genes involved
in fatty acid metabolism was significantly reduced in human gut
biopsies during the primary HIV infection (Fig. 2G). The
magnitude of this reduction was higher in chronic HIV infection in
A B C D
E F G
Fig. 2. Gut metabolomic profiling identifies mitochondrial fatty acid β-oxidation as a major target of SIV/HIV infection. (A) Pathway analysis of significantly
altered metabolites (q < 0.25, P < 0.05) was performed from ileal luminal contents of SIV-infected macaques compared to healthy controls. (B) Enrichment
analysis of significantly up-regulated metabolites (q < 0.25, P < 0.05) was performed using MetaboAnalyst (*P < 0.05). Arrows indicate pathways implicated in
metabolic pathways dependent on mitochondrial function. (C) Ratio of short- and medium-chain (C2–10) and (D) long and very-long chain (C12–24) acylcarnitines
to free carnitines was measured using UPLC-MS/MS byMetabolon. (E) Significant increases in short- and medium-chain acylcarnitines were detected in chronic SIV
infection. (F) Heatmap depicting expression of genes involved in fatty acid metabolism from gut tissue of chronic SIV-infected rhesus macaques (n = 4 in SIV−
group, n = 4 in SIV+ group) and (G) gut biopsies of individuals in primary stage of HIV infection (n = 3 in HIV group, n = 3 in control group) and chronic stage of
HIV infection in the absence of ART (n = 4 in HIV group, n = 10 in control group). N.S., not significant.
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the absence of ART. While initiation of ART has been shown to
exacerbate defects in mitochondrial fatty acid β-oxidation, our
data show that these defects are present even in absence of ART
in HIV-infected patients, highlighting the direct causal link be-
tween SIV/HIV infection and impaired mitochondrial fatty acid
metabolism in the gut.
To further define the mechanisms of HIV-induced enteropa-
thy and the direct role of HIV viral proteins (gp120 and Tat) and
IL-1β signaling, we assessed gut epithelial cell functionality and
permeability using a Caco-2 gut epithelial cell culture model in
vitro. Consistent with our findings in HIV and SIV infections in
vivo, both IL-1β and the combination of HIV proteins gp120 and
Tat induced marked disruption of intestinal barrier integrity and
function as detected by decreased expression and distribution of
tight junction protein ZO-1 (Fig. 3A) and decreased trans-
epithelial resistance across the cell monolayers (Fig. 3B). This
cellular disruption was linked to reduced mitochondrial function
as detected by a moderate decrease in mitochondrial ATP-linked
oxygen uptake with glucose and glutamine as substrates, dem-
onstrating that mitochondrial dysfunction may underlie epithe-
lial barrier disruption (Fig. 3 C and D). Addition of IL-1β alone
to Caco-2 cells reduced the spare respiratory capacity (by less
than 25%), suggesting either lower activity of complexes I, III,
and IV, or lower mitochondrial mass. However, the combination
of HIV gp120 and Tat lowered both basal respiration (by less
than 20%) and spare respiratory capacity (by less than 40%) in
Caco-2 cells (Fig. 3 E and F). Our findings map the pathogenic
effects of HIV antigens to disruption of either complex I, III, and
IV, or mitochondrial mass. These results are consistent with
findings in isolated lymphocytes from HIV-infected patients
(24). Our study links mitochondrial impairment to gut epithelial
barrier disruption in HIV and SIV infections. To define the precise
role of mitochondrial-derived ATP in regulating epithelial tight
junctions, we examined the effect of specific inhibitors of complex
I (rotenone), complex III (antimycin), and complex V (oligomycin)
individually in inducing disruption of tight junction ZO-1
distribution in Caco-2 cells (Fig. 3G). As expected for mito-
chondrial poisons that block the mitochondrial ATP production
with (antimycin > rotenone > oligomycin) or without significant
increased reactive oxygen species (ROS) production (oligomycin),
inhibition of complex III or V resulted in marked disruption of
ZO-1 distribution, while complex I induced modest changes in
ZO-1 expression. These differential effects indicated that increased
ROS was not mediating the disruption of ZO-1 expression, that
mitochondrial ATP was critical for this expression. These results
also underlined the relevance of fatty acid oxidation in which the
ratio of FADH2-to-NADH is higher (with lower involvement of
complex I) than that of glucose alone. Since these barrier defects
were identical to those induced by viral proteins or IL-1β on Caco-
2 cells, we hypothesized that mitochondria and catabolism of
specific substrates at the mitochondrial level were the target of
HIV infection, thereby sustaining gut epithelial disruption.
Rapid Repair of Epithelial Barriers in Chronic SIV Infection Independent
of Mucosal CD4+ T Cell Restoration after L. plantarum Administration.
We sought to explore whether the gut epithelial barrier could be
targeted for rapid repair/renewal in HIV infection even during the
state of incomplete mucosal immune recovery. We utilized the
ligated intestinal loop model in rhesus macaques with chronic
SIV infection to examine rapid and direct effects of probiotic
L. plantarum administration on the recovery of gut epithelial
disruption. Intestinal loops in healthy, uninfected controls (n = 4)
and macaques infected with SIV for 10 wk (n = 4) were injected
with L. plantarum from which tissue samples and luminal contents
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Fig. 3. Gut epithelial tight junctions are disrupted by HIV envelope, Tat, and IL-1β through inhibition of mitochondrial respiration. Epithelial tight junction
permeability in Caco-2 cells was measured after 5-h treatment with HIV gp120 (0.1 μg/mL) + Tat (1.4 μg/mL) or IL-1β (10 ng/mL) by (A) distribution of ZO-1
immunostaining (magnification: 63×) and (B) transepithelial electrical resistance (TEER) across the cell monolayer. (C) OCR in Caco-2 cells was detected using
Seahorse XFe24 after (D) 5-h treatment with HIV gp120 + Tat or IL-1β, and significant alterations (P < 0.05) were observed in (E) basal respiration and (F) spare
respiratory capacity. (G) Inhibition of mitochondrial respiration by 5-h treatment with rotenone, antimycin, and oligomycin altered tight junction protein
ZO-1 distribution (magnification: 63×) by immunohistochemistry. N.S., not significant.
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were analyzed after 5 h (SI Appendix, Fig. S6). The 16S rRNA
bacterial sequence analysis showed that L. plantarum was readily
detectable in these loops (SI Appendix, Fig. S7A) and the viability
and metabolic functionality of L. plantarum was not impaired in
virally infected and inflamed gut or in the context of resident
gut microbes (SI Appendix, Fig. S7B). It was very striking that
administration of L. plantarum for 5 h significantly increased
ZO-1 expression in the epithelium of intestinal loops of chroni-
cally SIV-infected animals (Fig. 4A), as indicated by quantification
of ZO-1 fluorescence intensity (Fig. 4B). Transcriptomic analysis
revealed a similar trend of increased gene-expression regulat-
ing gut barriers following L. plantarum administration (Fig. 4C).
Suppression of WNT pathway genes regulating intestinal ho-
meostasis, proliferation, and differentiation was observed in SIV
infection, which was rapidly reversed after L. plantarum ad-
ministration (SI Appendix, Fig. S8 A and B). Increased ex-
pression of Ki67, a cell proliferation marker in intestinal crypts
was noted (SI Appendix, Fig. S8 C and D). Reduced IL-1β pro-
tein production was also seen in intestinal crypts in chronic SIV
infection (Fig. 4 D and E) and decreased expression of IL-1β and
associated genes (Fig. 4F) which was verified on qRT-PCR (SI
Appendix, Fig. S9). No detectable changes were observed in the gut
viral loads and laminal propria CD4+ T cell percentages of in-
testinal loops after administration of L. plantarum as compared to
untreated controls (SI Appendix, Fig. S10). Our results suggest
that L. plantarum can be used to target intestinal epithelial
barrier repair, prior to gut immune cell recovery.
L. plantarum-Induced Intestinal Epithelial Repair In Vivo through
Mitochondrial Rescue. We investigated the capacity of L. planta-
rum to repair gut epithelial barrier disruption in SIV infection
through rapid rescue of cellular, molecular, and functionality
of mitochondria. We examined mitochondrial morphology (by
transmission electron microscopy, TEM), mitochondrial gene
expression (DNA microarrays), and mitochondrial metabolism
(metabolomics) in intestinal tissues and their contents.
Electron micrographs revealed a large number of mitochon-
dria located at the apical end adjacent to epithelial cell junctions
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semiquantitated using Imaris v8.2, and (C) broad transcriptomics analysis of genes involved in gut barrier function. Localization of IL-1β (magnification: 20×)
in intestinal crypts was (D) detected by immunohistochemical staining and (E) semiquantitated using Imaris v8.2. (F) Heatmap of genes associated with IL-1β
expression was analyzed using gene-expression microarrays of ileal tissues. N.S., not significant.
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that provide contact between neighboring cells in the ileum (Fig.
5A). These findings suggest the dominant role of mitochondrial
ATP at sustaining the functionality of epithelial tight junctions.
Images from the ileum of healthy SIV− animals showed that total
mitochondria occupied about 20% of each high-power field (Fig.
5B) with an average mitochondrial area of 0.1 μm2 (Fig. 5C).
Mitochondrial matrix exhibited parallel stacks of ordered cristae
with light intracrystal space and dark matrix. Intracellular mito-
chondrial distribution seemed mostly aligned longitudinally,
parallel, and in close proximity to tight junctions. In SIV-infected
tissues, mitochondrial mass was decreased by almost half, with a
more circular and less tubular shape characteristic of damage
mitochondria undergoing fission, a process that is typically fol-
lowed by autophagy or mitophagy (Fig. 5 D–F). In some cases,
mitochondria show rudimentary cristae (fragmented) and large,
empty central matrix spaces (Fig. 5A, arrows). These changes
were similar to those observed in cells dependent on glycolytic
metabolism (25), and cristae and matrix swelling are observed in
a variety of conditions involving stress and hypoxia (26–28). In
addition, the cristae fragmentation in SIV-infected macaques
produced a honeycomb-like pattern in cross-section (Fig. 5A,
asterisks), reflecting mitochondria under stress conditions. While
there were fewer dense granules per mitochondrion in SIV in-
fection compared to healthy controls (Fig. 5G), granule size was
significantly larger (Fig. 5 H and I). Mitochondria not containing
dense granules were much larger than mitochondria with granules,
and a corresponding decrease in the density of their matrices
were noted.
After SIV-infected ileal loops were incubated with L. plantarum,
TEM images revealed a mitochondrial morphology intermediate
between healthy controls and SIV-infected ileal loops without
bacteria. While the area of the field occupied by mitochondrial
mass was still lower, similar to that of SIV+ animals (Fig. 5A), the
average mitochondrion area was improved (Fig. 5B). Mitochon-
dria morphology was characterized by less circularity compared to
both healthy controls and those SIV+, with a tubular shape similar
to that of healthy controls. (Fig. 5 D–F). Still evident, some mi-
tochondria had a honeycomb pattern (Fig. 5A, asterisks) with no
clear definition of cristae. Although the number of dense body
granules did not change from SIV+ animals, the granule size was
larger, likely indicating increased capacity to accumulate calcium
phosphate as a result of improved membrane potential. Our
findings identify an accumulation of aberrant mitochondria with
lower mass and disrupted distribution and morphology as a result
of SIV/HIV enteropathy.
To investigate the role of L. plantarum in promoting mito-
chondrial biogenesis in inflamed gut mucosa during SIV in-
fection, we measured the expression of mitochondrially encoded
genes from ileal tissue following L. plantarum administration as
compared to untreated controls. Mitochondrial genes encoding
subunits of complex I (ND1, ND2, ND3, ND4, ND4L, ND5, and
ND6), complex III (CTYB), complex IV (COX1, COX2, and
COX3), and complex V (ATP6, ATP8) were all down-regulated
in SIV infection compared to uninfected controls (Fig. 6A).
Administration of L. plantarum increased the expression of all
these genes, supporting the notion that L. plantarum improves
the gene expression of key subunits of the electron transport
chain in chronic SIV infection. In addition, the decreased ex-
pression of genes associated with fatty acid metabolism in SIV
infection was reversed after exposure to L. plantarum, indicating
an improved capacity to utilize fatty acids for energy (Fig. 6B).
Increased gene-expression levels of PGC-1α following administra-
tion of L. plantarum suggested that host mitochondrial metabolism
and biogenesis may be a repair mechanism for gut homeostasis.
Furthermore, accumulation of dicarboxylic acylcarnitines, a
marker of impaired fatty acid β-oxidation in chronic SIV in-
fection, was reduced after administration of L. plantarum (Fig.
6C). These findings further elucidate the positive impact of bac-
teria at improving mitochondrial mass, morphology, and energy-
producing pathways.
We assessed functional restoration of mitochondria by metab-
olomic analysis of luminal contents from intestinal loops with or
Fig. 5. Protective effects of L. plantarum on mitochondrial structure and density in SIV-infected gut. (A) Mitochondrial structure and morphology in apical
enterocytes of ileum from healthy controls (n = 4) and SIV-infected macaques (n = 4) with and without L. plantarum administration (n =4) (Scale bars, 2 μm;
500 nm in the enlargments.). Mitochondrial mass was evaluated using (B) total mitochondrial area (%) and (C) individual mitochondrial area (μm2). Mito-
chondrial morphology was assessed using (D) circularity, (E) tubularity, and (F) the collective aspect ratio. Granule bodies and their dimensions were measured
by (G) enumeration per mitochondrion, (H) individual granule area (μm2), and (I) collective size per granule count. Data are reported as Tukey’s box plots
showing median and 1.5IQR. Outliers, shown as empty circles, were included in the statistical analysis.
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without L. plantarum administration. While free fatty acid metabolite
levels decreased in SIV infection, short- and medium-chain fatty
acids were increased, indicating a lower catabolism of fatty acids that
do not use the carnitine transporters (Fig. 6D). In support of
this notion, fatty acids are diverted to peroxisomal and microsomal
fatty acid ω-oxidation to compensate for incomplete mitochondrial
β-oxidation. The impact of SIV infection on mitochondrial function
in the gut was characterized by a metabolic switch to induce lipolysis
and production of free fatty acids, excessive and incomplete fatty
acid β-oxidation, and accumulation of organic acid intermediates
of the tricarboxylic acid (TCA cycle) leading to TCA overload.
Following L. plantarum administration, significant decreases in
A B C
D E
F G
Fig. 6. L. plantarum remodels host mitochondrial bioenergetics and ROS production in SIV infection. Heatmap of (A) mitochondria-encoded genes and (B)
genes regulating fatty acid metabolism in the ileum of chronic SIV-infected macaques after incubation with L. plantarum for 5 h (n = 4 in SIV-LP+ group, n =
4 in SIV+ LP+ group). (C) Metabolomic analysis of fatty acid components of ileal contents revealed significant changes in the presence of dicarboxylic acylcarnitines
(P < 0.05). Metabolite intermediates involved in mitochondrial bioenergetics were altered in (D) chronic SIV infection and (E) after administration of L. plantarum.
(F) Mitochondrial ROS production (yellow arrows, 40×, zoom 2.5×) following treatment with HIV gp120 + Tat and cell-free L. plantarum supernatant in Caco-
2 cells. (G) Data are reported as Tukey’s box plot (median and interquartile range), showing MitoSOX fluorescence intensity data normalized by cell area,
quantified with ImageJ on at least 100 cells per condition. Statistical analysis was performed with ANOVA followed by Kruskal–Wallis post hoc test for multiple
comparisons. Open circles represent outliers, which were included in the statistical analysis. N.S., not significant.
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ω-oxidation derived products were accompanied by modest de-
creases in mitochondrial β-oxidation intermediates and members
of the TCA cycle (Fig. 6E). Our data suggest that L. plantarum
promptly alleviates TCA overload by directly utilizing fatty acids
or indirectly influencing host metabolic enzymes. There were no
significant changes in glycolysis associated with SIV infection.
However, a similar level of increased glycolytic flux and lactate
production was observed following L. plantarum administration
in both SIV-infected and uninfected ileal loops, suggesting that
L. plantarum increased glycolytic intermediates regardless of
infection status (SI Appendix, Fig. S11). Therefore, glycolysis may
not play a major role in SIV pathogenesis in the gut and that
luminal contents represent a combination of bacterial-derived as
well as host-derived metabolites, as we have previously reported
(29). To investigate whether L. plantarum impacts mitochon-
drial ROS production, we measured mitochondrial-derived
ROS using MitoSOX staining of Caco-2 epithelial cell cultures
(Fig. 6F). Addition of cell-free L. plantarum supernatant prevented
the increase in mitochondrial ROS production associated with
HIV gp120 and Tat treatment (Fig. 6G), suggesting a potential
mechanism of repair associated with mitochondrial oxidative
phosphorylation.
PPARα-Mediated Metabolic Remodeling and Rapid Repair of Intestinal
Epithelial Barrier. We sought to identify the molecular signaling
mechanism of mitochondrial restoration in intestinal loops fol-
lowing L. plantarum administration. Analysis of the differential
gene expression in SIV-infected animals with L. plantarum com-
pared to untreated SIV-infected controls identified PPARα/
RXRα signaling to be suppressed in SIV infection but activated
after administration of L. plantarum (Fig. 7A). Further examina-
tion of PPARα target genes showed that L. plantarum exposure
recovered expression of genes involved in fatty acid metabolism
that were down-regulated by SIV infection (Fig. 7B). We cannot,
however, exclude a possibility that PPARα activation may also
have a direct effect on intestinal barrier gene expression, which
has also been implicated in our dataset (SI Appendix, Fig. S12).
To validate our findings of L. plantarum-driven PPARα acti-
vation in vivo, we utilized Caco-2 cell cultures in vitro and ex-
amined the effect of the cell-free L. plantarum supernatant media
on intestinal epithelial cells. The bacterial supernatant induced
marked activation of PPARα expression, which was comparable to
the magnitude of a PPARα agonist, fenofibrate (Fig. 7C). It is
possible that this mechanism involves the up-regulation of pyru-
vate dehydrogenase kinase 4 (PDK4), a downstream gene of
PPARα (along with others) that controls the metabolic switch
between aerobic glycolysis and fatty acid metabolism (Fig. 7D).
The enhancement of PDK4 after incubation with L. plantarum
supernatant suggests that the increased fatty acid metabolism was
the result of PDK4 up-regulation.
We investigated whether fenofibrate, a known PPARα agonist,
may restore mitochondrial function in the context of HIV in-
fection or prevent virus-induced damage. By using the extracellular
flux analyzer and oxygen consumption rate (OCR) measurements
in Caco-2 cells, we found that pretreatment with fenofibrate for
1 h prevented the moderate decrease in ATP production associ-
ated with HIV proteins gp120 and Tat treatments (Fig. 7E).
Fenofibrate prevented the decrease in basal respiration (SI Ap-
pendix, Fig. S13A) and spare respiratory capacity (SI Appendix,
Fig. S13B), highlighting its potential use to rescue ATP-linked
mitochondrial respiration in HIV infection in patients. Other
potential candidates for mitochondrial repair, such as the gluta-
thione precursor N-acetyl-cysteine, MitoTempo (a mitochond-
rially targeted scavenger of mitochondrial superoxide anion), and
the PPARγ agonist rosiglitazone did not prevent HIV-associated
decrease in spare respiratory capacity (SI Appendix, Fig. S14). No
glycolytic changes were observed on extracellular acidification rate
following the addition of gp120, Tat, or fenofibrate (SI Appendix,
Fig. S15). To support our findings in Seahorse measurements of
OCR, we determined complex I- and complex II-driven mito-
chondrial ATP synthesis rate by a previously established protocol.
While HIV gp120 + Tat treatment significantly decreased OCR in
the Seahorse assay, we did not observe changes in complex I- and
complex II-driven ATP synthesis, suggesting that the addition of
gp120 + Tat may inhibit fatty acid oxidation through complex III–V,
which might be the predominant source of energy in the cells
(Fig. 7 F and G). Furthermore, the addition of fenofibrate sig-
nificantly increased OCR in the Seahorse assay while decreasing
complex I- and complex II-driven ATP synthesis, suggesting that
fatty acid β-oxidation may be enhanced (30) at the expense of
complex I- and II-driven glucose oxidation (31), as previously
shown. Finally, pretreatment with fenofibrate or L. plantarum
supernatant prevented disruption of epithelial tight junctions
with HIV gp120 and Tat (Fig. 7 H and I). Our data suggest that
PPARα activation plays a critical role in protection against HIV-
induced intestinal barrier damage through improving mitochondrial
function (Fig. 7J).
Discussion
The success of current therapies and future strategies for HIV
eradication depends on near-complete recovery of the gut mu-
cosal compartment in HIV-infected patients (32). Even long-
term ART has not resulted in complete repair of gut lymphoid
tissues consistently in many HIV-infected individuals due to the
presence of low levels of residual viral replication and chronic
inflammation, and suboptimal regeneration of immune cells (33,
34). ART can effectively suppress viral replication but lacks the
ability to repair and renew disrupted lymphoid compartments.
Substantial efforts have been made to better incomplete immune
recovery. However, it remains underinvestigated why the gut
epithelial compartment, which has robust renewal capacity from
intestinal stem cells, is not fully renewed structurally and func-
tionally. Using the intestinal loop model in SIV-infected ma-
caques, we investigated enteropathic effects of SIV infection and
their reversal by probiotic L. plantarum administration. This
model allowed us to collect several samples within the same
animal to elucidate host–microbe interactions in virally inflamed
gut mucosa. Our study identified impaired mitochondrial func-
tion and PPARα signaling as a defining mechanism that con-
tributes to gut epithelial barrier disruption in SIV and HIV
infection. We demonstrate that intestinal barrier integrity and
function can be rapidly restored by probiotic L. plantarum
through PPARα activation independent of complete mucosal
immune recovery.
Our study maps several steps in mitochondrial function that
are disrupted during SIV infection. First, mitochondrial mor-
phology in the intestinal epithelial cells exhibit less mitochon-
drial mass, increased circularity, and fewer dense body granules,
suggesting potentially altered mitochondrial sequestration of
Ca2+, mitochondrial permeability, and apoptosis. Second, in-
clusion bodies and cristae loss may represent accumulation of
misfolded proteins as a result of increased oxidative stress and
failure to assemble subunits of, for example, mitochondrial
ATPase (35). Most importantly, disrupted mitochondrial mor-
phology is consistent with functional deficit. Inhibition of fatty
acid β-oxidation of short- and medium-chain fatty acids in the gut
occurred in both SIV and HIV infection and correlated with
structural distribution of ZO-1 tight junction protein. Large
numbers of mitochondria observed in apical enterocytes suggest
that regulation of cell–cell junctions are linked to mitochondrial
ATP production. Using inhibitors of mitochondrial complexes I,
III, and V, we show that reducing mitochondrial ATP produc-
tion leads to disruption of ZO-1 expression. Our data show
that metabolic and transcriptional reprogramming of intestinal
epithelial cells driving intestinal barrier permeability implicates
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mitochondrial dysfunction and this can also increase risk of
systemic infection (36).
We previously reported that increased IL-1β expression in
Paneth cells drives early disruption of gut barriers in SIV in-
fection (4). We found that increased IL-1β expression persists
through chronic SIV infection and asked whether mitochondrial
dysfunction contributes to IL-1β–induced intestinal barrier dis-
ruption. Addition of IL-1β or the combination of HIV proteins
gp120 and Tat induced epithelial barrier disruption in Caco-
2 cells, which associated with a decrease in mitochondrial basal
and spare respiratory capacity. Defects in neuronal mitochon-
drial membrane permeability and epithelial tight junction in-
tegrity have been observed following treatment with HIV proteins
(18, 37). Our study links the disruption of intestinal epithelial
barrier integrity with mitochondrial dysfunction. Understanding
the mechanisms by which the epithelial barrier is disrupted in HIV
infection enables the development of novel strategies for mucosal
restoration.
Commensal gut microbiota regulate integrity of intestinal
epithelial barriers. Gut dysbiosis and leaky intestinal barriers in
HIV infection may contribute to microbial translocation and
chronic immune activation (38). We previously reported that L.
plantarum can rapidly repair epithelial barrier integrity at 2.5 d
post-SIV infection (4), and sought to investigate whether gut
barriers could be repaired in chronic viral infection. Adminis-
tration of L. plantarum in intestinal loops led to rapid restora-
tion of intestinal barrier function independent of CD4+ T cell
recovery. This rapid rate of recovery (within 5 h) in SIV-inflamed
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Fig. 7. PPARα-mediated metabolic remodeling restores mitochondrial function and epithelial tight junction integrity. (A) Canonical gene pathway analysis of
significantly altered genes (−1.5 < FC >1.5, P < 0.05) was performed on gene-expression microarrays using Ingenuity Pathway Analysis. (B) Heatmap of PPARα
target genes during chronic SIV infection and after administration of L. plantarum. (C) Caco-2 cells treated for 24 h with fenofibrate (10 μM) or L. plantarum
cell-free supernatant (1:10 dilution in MEM media) were used in measurement of PPARα expression by real-time PCR. (D) Expression of PPARα target gene
PDK4 was increased compared to control. (E) OCR was measured by Seahorse XFe24 after Caco-2 cells were pretreated with fenofibrate (10 μM) or DMSO for
1 h before treatment with HIV gp120 (0.1 μg/mL) + Tat (1.4 μg/mL) for 5 h. Addition of fenofibrate reduced (F) complex I- and (G) complex II-driven ATP
synthesis. Effects of fenofibrate and L. plantarum supernatant on epithelial permeability was evaluated using (H) immunohistochemical staining of ZO-1 tight
junction protein expression (magnification: 63×) and (I) TEER measurements. (J) An illustration depicting metabolic regulation of gut barriers in SIV infection
and repair pathways following administration of L. plantarum. N.S., not significant.
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gut was remarkable. It was previously reported that L. plantarum
could strengthen intestinal barriers within 6 h in vitro (39) and in
8 h in chicks in vivo (40). Studies are limited that investigate the
impact of direct bacterial administration into intestinal loops and
subsequent host mucosal response. Introduction of microbes into
intestinal lumen can induce rapid host mucosal responses (9, 41).
Our analysis of metabolites from gut luminal contents following
the administration of L. plantarum revealed information about
both host-derived and bacterial-derived metabolic products
and mechanisms in host–microbe cometabolism. Many of these
metabolites are produced by both microbiota and the host.
Transcriptomic and metabolomic analyses of gut tissues identi-
fied up-regulation of mitochondrial fatty acid metabolism that
may be protective in SIV infection. In diet-induced obese mice,
probiotic Lactobacillus administration reduced fat accumulation
and promoted intestinal barrier function (42, 43). We observed
that L. plantarum also reduced IL-1β–induced inflammation,
which may further alleviate cytokine-induced mitochondrial dam-
age. Our findings reveal the synergism between gut microbes and
their host as a mechanism to enhance gut repair and healing
during HIV infection and ART.
Transcriptional and metabolic data in our study of L. plantarum-
administered intestinal loops enabled us to test the hypothesis that
activation of PPARα may restore fatty acid metabolism and renew
intestinal barrier integrity. Previous studies reported that Lacto-
bacillus spp. can modulate lipid metabolism and promote antiox-
idant capacity in mice and aging adults (42, 44). We show that
metabolites from L. plantarum can induce PPARα signaling in
Caco-2 cells to levels similar to cells stimulated by PPARα agonist
fenofibrate. Fenofibrate has been explored to improve mitochon-
drial biogenesis and function in several disease models (45, 46). In
our study, fenofibrate attenuated the decline in mitochondrial
spare respiratory capacity and epithelial barrier disruption induced
by gp120 and Tat. In accordance with findings in HIV-1 Tat-
induced diarrhea (47), our data suggest that PPARα signaling
may be critical in intestinal repair pathway to reverse mucosal
damage in HIV infection. The promotion of mitochondrial fatty
acid oxidation following activation of PPARα is likely due to
downstream expression of PDK4, a key component in meta-
bolic switching (48). Our findings from intestinal tissues of SIV-
infected rhesus macaques and HIV patients in vivo and epi-
thelial cell cultures in vitro reveal that viral infection down-regulates
PDK4 expression, which is overcome by activation of PPARα.
Activation of PPARα by fenofibrate also restores intestinal ep-
ithelial barriers in vitro, suggesting that leveraging cellular me-
tabolism may be useful in mucosal repair and warrant further
investigation in the clinical setting. PPARα agonists have been
shown to decrease IL-1β expression by deregulating caspase-1
and NLRP3, which is consistent with our observations follow-
ing L. plantarum administration (49). Fenofibrate has been
widely used in human patients to treat dyslipidemia and car-
diovascular disease with great success and negligible side effects
(50). Despite its ability to reduce coronary heart disease and
improve lipid profiles in HIV patients, limited data are available
on clinical outcomes (51). We demonstrate that mitochondrial
fatty acid metabolism in the intestinal epithelium is impaired in
SIV-infected rhesus macaques and in HIV-infected patients.
Investigating mechanisms underlying metabolic changes high-
light new opportunities for fenofibrate and PPARα signaling in
gut mucosal health.
Our basic investigation into the mechanism of how epithelial
barriers are regulated in chronic SIV infection paved the way to
translational findings that may be leveraged for gut mucosal
restoration. In the clinical setting, HIV patients on ART, par-
ticularly those receiving HIV protease inhibitors, develop insulin
resistance reflected as lipodystrophy and altered fatty acid me-
tabolism (52, 53). It is noteworthy that alterations in mitochon-
drial fatty acid metabolism are not unique to SIV and HIV
infections. Cytomegalovirus, dengue virus, and hepatitis C virus
utilize host fatty acid metabolism to enhance viral replication
(54, 55). A number of inflammatory enteropathies, including
inflammatory bowel disease and type 2 diabetes, share common
features with HIV infection (56, 57). Investigation across dis-
eases may provide crucial insight on how to repair “leaky gut,”
chronic inflammation, and mitochondrial dysfunction. Although
more widely used in treatment of lipodystrophy in diabetes pa-
tients, fibrate drugs have also been successfully used concur-
rently with ART treatment to reduce hyperlipidemia in HIV
infection (53, 58). Our findings identify additional benefits from
the use of fenofibrate for modulating the gut epithelial cell
metabolism and functionality. We show that impaired PPARα
signaling, mitochondrial mass and morphology, and mitochon-
drial fatty acid β-oxidation are defining mechanisms for restoring
the integrity of gut barriers during chronic SIV infection. Our data
highlight the opportunity to elucidate the evolutionary synergism
between host mitochondria and gut microbes to restore mucosal
health and achieve full immune recovery.
Methods
Animal Experiments and Viral Infection. The study design is described in detail
in SI Appendix. A total of 16 male rhesus macaques were enrolled in
the study, 12 of which were infected intravenous with 1,000 TCID50 of
SIVmac251 for 10 wk (chronic infection) and 4 of which served as SIV−
controls. Of the 12 SIV-infected macaques, 5 received ART, starting at 10-wk
postinfection for at least 10 to 20 wk, while 3 remained untreated (7). At
10-wk postinfection, the remaining 4 SIV-infected macaques, along with
4 uninfected macaques, underwent ligated ileal loop surgery to assess the
effects following L. plantarum administration. Details of the procedures,
sample collection, and data analyses are described in SI Appendix. Viral
loads, CD4 and CD8 T cell numbers in peripheral blood were determined
during the course of infection, as previously reported (7). Statistical analysis
is described in SI Appendix.
Ethics Statement. All macaques involved in the study were housed at the
California National Primate Research Center (CNPRC). The CNPRC is fully
accredited by the American Association for Accreditation of Laboratory
Animal Care for nonhuman primate housing, breeding, and research. In addi-
tion, the CNPRC upholds standards set by the US Department of Agriculture,
the Animal Welfare Act, and the Food and Drug Administration. In the du-
ration of the study, animals were observed daily by trained CNPRC ani-
mal technicians, and significant health observations recorded. Signs, which
are monitored daily, include hydration, stool quality, appetite, attitude, and
activity level. Animals were euthanized in accordance with the AVMA
Guidelines for the Euthanasia of Animals: 2013 Edition (ref. 59, section 2.3).
Human Patient Samples. To translate our findings in HIV, gene-expression data
from 15 patients from our previous studies were utilized to investigate fatty
acid metabolic genes (2, 60). Written informed consent was obtained from
all participants and subsequently approved from the Institution Review
Board of the University of California Davis and the protocol is current. Je-
junal biopsies were collected from 3 patients in primary HIV infection, after
the initiation of ART, and ∼1 y after ART interruption. Jejunal biopsies from 2
other ART-naïve patients were taken and compared to 10 HIV-seronegative
individuals.
Data Availability. The sequences and metadata reported here are available at
the Gene Expression Omnibus (GEO) database (accession no. GSE139271) and
National Center for Biotechnology Information (NCBI) Bioproject (accession
no. PRJNA578916).
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